Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ipilimumab + MIW815 |
Synonyms | |
Therapy Description |
MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling, resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ipilimumab | Yervoy | BMS-734016 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
MIW815 | ADUS100|ADU-S100|NVP-MIW815 | STING1 Agonist 19 | MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling (STING1), resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787, PMID: 31355488). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02675439 | Phase I | Ipilimumab + MIW815 MIW815 | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |